Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5193762 | 0.94 | PTGS2 (0.55) | HTTNPC1HPGDMAPK1RAB9A | |
| SCHEMBL981614 | 0.90 | HTT (0.62) | HTTNPC1HPGDMAPK1RAB9A | |
| SCHEMBL199705 | 0.90 | HPGD (0.55) | HTTNPC1HPGDMAPK1RAB9A | |
| SCHEMBL5676244 | 0.89 | HTT (0.60) | HTTNPC1HPGDMAPK1RAB9A | |
| SCHEMBL5680768 | 0.88 | BACE1 (0.47) | HTTNPC1HPGDMAPK1RAB9A | |
| SCHEMBL5676717 | 0.87 | HTT (0.58) | HTTNPC1HPGDMAPK1RAB9A | |
| SCHEMBL5680720 | 0.87 | HTT (0.58) | HTTNPC1HPGDMAPK1RAB9A | |
| SCHEMBL1023152 | 0.86 | HPGD (0.52) | HTTNPC1HPGDMAPK1RAB9A | |
| SCHEMBL30628001 | 0.86 | HPGD (0.52) | HTTNPC1HPGDMAPK1RAB9A | |
| SCHEMBL6351058 | 0.86 | NPC1 (0.72) | HTTNPC1HPGDMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | ZHAO BAIYI | 2006-02-16 | — | — | US | disclosed |
| EP-1620447-A1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | Exxonmobil Chemical Patents Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2003102006-A1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | COMT, CD69, SPR | HTT 2378/4885NPC1 3879/4885HPGD 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.